Loading…
OrbiMed
Actively investingInvest across the full healthcare capital structure — from private venture to public crossover — in companies advancing differentiated therapeutics and platforms.
About
Global healthcare investment firm spanning venture, growth, and public equities across biopharmaceuticals, medical devices, and diagnostics.
Investment thesis
Invest across the full healthcare capital structure — from private venture to public crossover — in companies advancing differentiated therapeutics and platforms.
Deterministic scores · rules-based, not AIiHow these scores are obtained: each one is computed from this profile's listed attributes — capability checkboxes, certifications, capacity figures and coverage — by a fixed formula, recomputed on every page load. Deterministic and rules-based means the score comes from a fixed, transparent formula over listed attributes — the same inputs always produce the same score. It is not AI: there is no model, no learning, and no hidden weighting. Whether a score is relevant to you depends on your specific project: a capability that raises the number may not matter for your work, and a niche strength your project needs may barely move it. Capability scores are a directional starting point, not a verdict. A lower score does not disqualify a company or consultant, and no decision should rest on the score alone — always contact the company directly to confirm the specifics for your project.
Manufacturing focus iAdds 25 points if the firm flags GMP-manufacturing interest, plus 9 points per manufacturing-related technical interest listed (sterile injectables, fill-finish, GMP software, QC automation, and similar), capped at 45, and 10 points per manufacturing strategic category (CDMO investments, manufacturing infrastructure, continuous manufacturing, and similar), capped at 30. Levels: 75+ Manufacturing-focused | 50-74 Manufacturing-active | 25-49 Selective | below 25 Therapeutics-focused. Whether this dimension matters for you depends on your specific project.
19Therapeutics-focused
Portfolio strength iAdds 4 points per portfolio company, capped at 50, plus 6 points per realized exit, acquisition, or IPO, capped at 30, and a further 7 points per IPO, capped at 20. Shows 0 with a Building label when no portfolio companies are listed. Levels: 80+ Proven track record | 60-79 Strong | 40-59 Active | below 40 Emerging. Whether this dimension matters for you depends on your specific project.
52Active
Syndicate network iAdds 5 points per co-investor listed, capped at 40, plus 9 points for each frequent or recurring co-investor relationship, capped at 35, and 9 points for each strategic partner (corporate, pharma, crossover, or sovereign investor), capped at 25. Shows 0 with an Emerging label when no co-investors are listed. Levels: 75+ Deeply networked | 50-74 Well-connected | 25-49 Building network | below 25 Emerging. Whether this dimension matters for you depends on your specific project.
77Deeply networked
Mfg due-diligence iScores each diligence area by depth (3 points expert, 2 in-depth, 1 standard) times 2, capped at 45, plus 5 points per recognized regulatory framework covered (FDA, EMA, MHRA, PMDA, and similar), capped at 25, plus 20 points for in-house or hybrid technical diligence capability (12 for external), and 10 if the firm reviews inspection history. Levels: 80+ Expert diligence | 60-79 Rigorous | 35-59 Standard | below 35 Light. Whether this dimension matters for you depends on your specific project.
67Rigorous
Preferred stages
Series BSeries CGrowthCrossover / Pre-IPO
Therapeutic focus
OncologyRare diseaseCardiometabolicInfectious disease
Geographic focus
GlobalNorth AmericaAsia-Pacific
O
OrbiMed
VC / Investment firm · United States
Live record · illustrative seed data · scores deterministic, rules-based — not AI.